CST651
CST651 (PROTAC CDK4/6 degrader 34) is a selective cyclin-dependent kinase CDK4/6 PROTAC degrader with DC50 values of 20 nM and 5.1 nM, respectively. CST651 recruits the VHL E3 ubiquitin ligase to mediate the ubiquitination and proteasomal degradation of CDK4/6. CST651 inhibits cancer cell proliferation and migration. CST651 can be used in research related to breast cancer, multiple myeloma, acute myeloid leukemia, and acute lymphoblastic leukemia.
(Pink: CDK4 and CDK6 ligand (HY-50767); Blue: VHL ligand (HY-125905); Black: linker (HY-W017440)).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2489241-16-7
- 分子式: C56H72FN11O9S
- 分子量:1094.30
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
PROTACs アイソフォーム固有の製品をすべて表示
More
生物活性
|
CDK6 5.1 nM (DC50, In MM.1S cells) |
CDK4 20 nM (DC50, In MM.1S cells) |
VHL |
CST651 (0.0001-1 μM; 3-96 h) potently and selectively degrades CDK6 but not CDK4 in MM.1S cells via the CRL2VHL- and proteasome-dependent pathway, with a CDK6 DC50 of 5.1 nM, and exerts a durable degradation effect after washout[2].
CST651 (0.1 nM-0.1 mM; 96 h) inhibits the viability of HEL acute myeloid leukemia cells with an IC50 of 0.45 μM, exhibiting stronger potency than Palbociclib (HY-50767)[2].
CST651 (0.1 μM; 24 h) reduces the migratory capacity of MDA-MB-231 breast cancer cells by 29% at a concentration of 0.1 μM, and its efficacy is superior to that of Palbociclib[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human multiple myeloma MM.1S cells
-
Concentration:0.0001-1 μM (16 h); 0.1 μM (co-treated with 10 μM VH298, MG132, or MLN4924, 16 h); 0.1 μM (washout followed by 3-96 h incubation); 0.1 μM (96 h)
-
Incubation Time:16 h (single treatment, co-treatment); 3-96 h (postwashout incubation); 96 h
-
Result:Induced concentration-dependent degradation of CDK6 and CDK4, with a DC50 of 5.1 nM for CDK6 and >95% maximum CDK6 degradation at 100 nM after 16 h.
Reduced CDK6 levels to 1.4% and CDK4 levels to 44% at 0.1 μM after 16 h.
Abrogated CDK4/6 degradation when co-treated with 100-fold excess VH298.
Prevented proteasomal degradation of CDK6 when co-treated with MG132 or MLN4924.
Maintained CDK6 degradation for up to 72 h post-washout, with CDK6 levels remaining below 50% of baseline.
-
Cell Line:human acute myeloid leukemia HEL cells
-
Concentration:10-10-10-4 M
-
Incubation Time:96 h
-
Result:Inhibited HEL cell viability with an IC50 of 0.45 μM.
Exhibited greater potency than palbociclib (IC50 = 4.16 μM) and VHL-based PROTAC 27 (IC50 = 1.54 μM).
-
Cell Line:human breast cancer MDA-MB-231 cells
-
Concentration:0.1 μM
-
Incubation Time:24 h
-
Result:Reduced MDA-MB-231 cell migration by 29%.
Exhibited a greater effect than palbociclib (17% reduction).
化学情報
-
CAS 番号 2489241-16-7
-
分子量 1094.30
-
分子式 C56H72FN11O9S
-
SMILES
O=C1C(C(C)=O)=C(C2=CN=C(N=C2N1C3CCCC3)NC4=CC=C(N5CCN(CCOCCOCCOC6=CC(C7=C(C)N=CS7)=CC=C6CNC([C@H]8N(C([C@H](C(C)(C)C)NC(C9(CC9)F)=O)=O)C[C@H](O)C8)=O)CC5)C=N4)C
-
別名
PROTAC CDK4/6 degrader 34
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Kossakowski K, et al. FDA-approved kinase inhibitors in PROTAC design, development and synthesis. Journal of enzyme inhibition and medicinal chemistry. 2025 Dec;40(1):2542357. [Content Brief]
[2]. Steinebach C, et al. Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders. Chemical science. 2020 Apr 07;11(13):3474-3486. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
CST651 関連分類
HY-134303 関連分類
Powered by Bioz